RxDoctor Payments Data

Sang Kim, MD

Ophthalmology · Indianapolis, INNPI 1033119417

Payments from drug & device makers

$1,854in general payments, 2019–2025

Across 49 payments — averaging $37.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$448
  • Apellis Pharmaceuticals, Inc.$400
  • Regeneron Healthcare Solutions, Inc.$392
  • Genentech USA, Inc.$220
  • Alimera Sciences, Inc.$108
  • Eyepoint US, Inc.$102
  • plus $183 from 7 others

What the payments were for

  • Food & beverage$1,854100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,854 in reported general payments places this provider in the 55th percentile of 266 ophthalmology providers in Indiana.

See all ophthalmology providers in Indiana

Medicare billing

Part B allowed, 2024
$1,192,225
Medicare patients
720
Services billed
12,463

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol74$17,036
Dorzolamide Hcl954$16,272
LumiganBimatoprost24$12,671
Prednisolone Acetate136$6,524
Ketorolac Tromethamine145$5,010
CombiganBrimonidine Tartrate/Timolol14$4,545
Brinzolamide16$3,575
Latanoprost98$998
Brimonidine Tartrate55$898
Timolol Maleate79$768
Acetazolamide16$591
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat30$475
Tobramycin43$323
Ofloxacin12$106

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan$28$17,21638 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 266 ophthalmology providers in Indiana.

Other ophthalmology in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →